PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Negative EBIT growth while RVPH is at 34.10%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-20.40%
Negative operating income growth while RVPH is at 34.10%. Joel Greenblatt would press for urgent turnaround measures.
-19.78%
Negative net income growth while RVPH stands at 22.59%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.20%
EPS growth at 50-75% of RVPH's 22.58%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
12.20%
Diluted EPS growth at 50-75% of RVPH's 22.58%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
35.62%
Share count expansion well above RVPH's 0.24%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
35.62%
Diluted share count expanding well above RVPH's 0.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-10.88%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
87.84%
Positive OCF/share growth while RVPH is negative. John Neff might see a comparative advantage in operational cash viability.
86.67%
Positive 3Y OCF/share CAGR while RVPH is negative. John Neff might see a big short-term edge in operational efficiency.
-1279.04%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
88.03%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
86.27%
Positive short-term CAGR while RVPH is negative. John Neff would see a clear advantage in near-term profit trajectory.
1371.24%
Equity/share CAGR of 1371.24% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-83.09%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.87%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Negative asset growth while RVPH invests at 0.76%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-34.03%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-19.69%
We’re deleveraging while RVPH stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.98%
We increase R&D while RVPH cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
58.15%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.